A detailed history of Us Bancorp \De\ transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 247 shares of KROS stock, worth $2,924. This represents 0.0% of its overall portfolio holdings.

Number of Shares
247
Previous 285 13.33%
Holding current value
$2,924
Previous $13,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$41.68 - $58.07 $1,583 - $2,206
-38 Reduced 13.33%
247 $14,000
Q2 2024

Aug 06, 2024

SELL
$44.58 - $66.89 $4,903 - $7,357
-110 Reduced 27.85%
285 $13,000
Q1 2024

May 07, 2024

BUY
$41.26 - $70.48 $1,980 - $3,383
48 Added 13.83%
395 $26,000
Q4 2023

Feb 09, 2024

BUY
$27.12 - $41.05 $9,410 - $14,244
347 New
347 $13,000
Q3 2022

Oct 27, 2022

BUY
$27.8 - $40.12 $389 - $561
14 Added 34.15%
55 $2,000
Q3 2021

Nov 10, 2021

BUY
$29.27 - $43.71 $1,200 - $1,792
41 New
41 $2,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $305M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.